Relmada Therapeutics Inc RLMD Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$3.90 up $0.13, 3.45% at close Nov 6
Last close · Previous close $3.77
- Market cap
- At the Nov 6 close
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$3.90up $0.13, 3.45%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$3.77Nov 5
- Volume1.49MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.75MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.65 to $8.00; now $3.90
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
RLMD beat the S&P 500 in 2 of 7 periods.
| Period | RLMD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RLMD: up 18.9% S&P 500: down 5.6% | RLMD beat the S&P 500 by 24.5 percentage points Beat |
| 3M | RLMD: down 27.4% S&P 500: down 4.1% | RLMD trailed the S&P 500 by 23.3 percentage points Trailed |
| YTD | RLMD: down 19.3% S&P 500: up 8.7% | RLMD trailed the S&P 500 by 28.0 percentage points Trailed |
| 1Y | RLMD: up 49.4% S&P 500: up 10.9% | RLMD beat the S&P 500 by 38.5 percentage points Beat |
| Long term | ||
| 3Y | RLMD: up 24.6% S&P 500: up 75.0% +7.6% vs +20.5% a year | RLMD trailed the S&P 500 by 50.4 percentage points Trailed |
| 5Y | RLMD: down 85.2% S&P 500: up 67.8% −31.7% vs +10.9% a year | RLMD trailed the S&P 500 by 153.0 percentage points Trailed |
| 10Y | RLMD: down 2.5% S&P 500: up 313.1% −0.3% vs +15.2% a year | RLMD trailed the S&P 500 by 315.6 percentage points Trailed |
$10,000 invested in RLMD 10 years ago (Nov 4, 2016) would be worth about $9,750 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
RLMD beat the S&P 500 in 2 of 7 periods.
| Period | RLMD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RLMD: up 18.9% S&P 500: down 5.6% | RLMD beat the S&P 500 by 24.5 percentage points Beat |
| 3M | RLMD: down 27.4% S&P 500: down 4.3% | RLMD trailed the S&P 500 by 23.1 percentage points Trailed |
| YTD | RLMD: down 19.3% S&P 500: up 7.8% | RLMD trailed the S&P 500 by 27.1 percentage points Trailed |
| 1Y | RLMD: up 49.4% S&P 500: up 9.7% | RLMD beat the S&P 500 by 39.7 percentage points Beat |
| Long term | ||
| 3Y | RLMD: up 24.6% S&P 500: up 68.8% +7.6% vs +19.1% a year | RLMD trailed the S&P 500 by 44.2 percentage points Trailed |
| 5Y | RLMD: down 85.2% S&P 500: up 56.9% −31.7% vs +9.4% a year | RLMD trailed the S&P 500 by 142.1 percentage points Trailed |
| 10Y | RLMD: down 2.5% S&P 500: up 252.6% −0.3% vs +13.4% a year | RLMD trailed the S&P 500 by 255.1 percentage points Trailed |
$10,000 invested in RLMD 10 years ago (Nov 4, 2016) would be worth about $9,750 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$74.40
Closing high on . Now 94.8% below that record.
Split-adjusted daily closes since Oct 9, 2014.
Stock splits
2
Latest: 1-for-4 on . Share counts adjust after each split.
Both splits
- 1-for-4
- 1-for-5
Valuation
Financials
About Relmada Therapeutics Inc
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS) and metabolic disorders. Relmada’s experienced and dedicated team is committed to making a difference in the lives of patients and their families.
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
RLMD news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
RLMD stock FAQ
What is RLMD stock’s price today?
Relmada Therapeutics (RLMD) traded at $3.90 at the close on , up $0.13 (3.45%) from the previous close of $3.77. Over the past 52 weeks it has traded between $2.65 and $8.00.
If you invested $1,000 in RLMD 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in RLMD on would be worth about $975 at the close on , a total return of −2.5%. The same $1,000 would be worth $148 if invested five years ago and $1,494 if invested one year ago. Past performance doesn’t predict future returns.
Does RLMD pay a dividend?
Relmada Therapeutics hasn’t paid a dividend in the last twelve months.
What is RLMD’s 52-week high and low?
Over the past 52 weeks RLMD has traded as low as $2.65 and as high as $8.00. At $3.90 at the close on , it is 51.3% below that high and 47.2% above the low.
What is RLMD’s all-time high?
RLMD’s highest closing price was $74.40 on , adjusted for stock splits. At $3.90 at the close on , it is 94.8% below that record.
Has RLMD stock ever split?
Yes, twice: 1-for-5 on ; 1-for-4 on .
How has RLMD stock performed?
Including dividends and measured to the close on , RLMD has returned −19.3% so far this year and +49.4% over the past year, and −85.2% over five years (−31.7% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What exchange does RLMD trade on?
Relmada Therapeutics trades on the Nasdaq under the ticker symbol RLMD. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.